AIIMS Bathinda to roll out Renal transplant centre

Bathinda: AIIMS Bathinda is all set to launch Punjab’s first-ever renal transplant centre, marking a significant step forward in government healthcare services. The renal transplant program is anticipated to commence by the end of March after securing approval from the state government.

Dr Tarun Goyal, the official spokesperson for AIIMS has confirmed the ongoing inspections by teams from the Director General of Medical Education and Research (DGMER), a part of the state health department, to facilitate approval. The establishment of this facility at AIIMS Bathinda is expected to alleviate the strain on kidney patients at PGIMER Chandigarh, the sole government-funded hospital in the region currently offering similar services. 
Dr Tarun Goyal informed Hindustan Times,” Departments of nephrology and urology, crucial for renal transplantation, are functional well for almost two years. We are fully equipped with a team of super specialists from different departments, including cardiology, paediatrics and anaesthesia, and an intensive care unit as per the protocol for organ transplants.” 

In the initial phase, only blood-related relatives will be accepted as donors for live renal transplants. This development addresses the absence of renal transplant services in public sector hospitals in Punjab. Associate professor in the urology department and transplant surgeon, Dr Kawaljit Singh Kaura will be serving as the nodal officer of the upcoming project and he told the Daily that during the second phase, the institute will initiate cadaveric transplants which will aim at harvesting kidneys from a brain-dead person with consent. 

“We already have 25 dialysis patients who need kidney transplants. We hope to get a renal transplant license from DGMER in another month. After that patients awaiting transplant will undergo various tests for undergoing surgery,” said Dr Kaura. 
The renal transplant department at PGIMER currently attracts patients from neighbouring states and even distant locations like the north-eastern states, Orissa, Bihar, Jharkhand, Uttar Pradesh, and Nepal. With a significantly lower cost compared to private facilities, the procedure at PGIMER is budget-friendly, totalling less than ₹1 lakh, covering medicines and a two-week hospital stay for both donor and recipient.
With AIIMS Bathinda setting up a renal transplant centre, a government facility will be able to provide similar renal services in line with PGIMER in Punjab. 

Powered by WPeMatico

SGLT2 inhibitors preferred oral antidiabetic for individuals with both NAFLD and T2D,reveals study

Nonalcoholic fatty liver disease (NAFLD) is prevalent among individuals with type 2 diabetes (T2D) and presents a significant health burden. While various oral antidiabetic drugs (OADs) have been used in NAFLD management, there is a lack of clarity on which class offers the best outcomes. NAFLD commonly coexists with T2D, posing challenges for management. Understanding which OADs are most effective in NAFLD treatment is crucial for optimizing patient care and improving outcomes.

A recent retrospective cohort study sought to address this gap by comparing the efficacy of different OADs in NAFLD regression and liver-related outcomes. This study was published in the journal of JAMA Internal Medicine by Heejoon and colleagues. The study, conducted using population-level data from Korea, included patients with T2D and NAFLD. Patients receiving sodium-glucose cotransporter 2 (SGLT2) inhibitors, thiazolidinediones, dipeptidyl peptidase-4 (DPP-4) inhibitors, or sulfonylureas in combination with metformin were analyzed. NAFLD regression and liver-related outcomes were assessed over a follow-up period.

  • The study involved 80,178 patients with type 2 diabetes and nonalcoholic fatty liver disease (NAFLD), with a mean age of 58.5 years, of which 53.6% were male.

  • Sodium-glucose cotransporter 2 (SGLT2) inhibitors, thiazolidinediones, and dipeptidyl peptidase-4 (DPP-4) inhibitors were associated with a significant reduction in NAFLD severity compared to sulfonylureas.

  • SGLT2 inhibitors exhibited the highest likelihood of NAFLD regression, followed by thiazolidinediones and DPP-4 inhibitors, when compared to sulfonylureas.

  • Only SGLT2 inhibitors were significantly associated with lower rates of adverse liver-related outcomes, including hospitalization, mortality, liver transplant, and hepatocellular carcinoma, compared to sulfonylureas.

The study suggests that SGLT2 inhibitors may be preferred over other OADs in individuals with NAFLD and T2D due to their superior efficacy in promoting NAFLD regression and reducing adverse liver-related outcomes. These findings underscore the importance of reevaluating prescribing practices and warrant further research to validate these results.

Reference:

Jang, H., Kim, Y., Lee, D. H., Joo, S. K., Koo, B. K., Lim, S., Lee, W., & Kim, W. Outcomes of various classes of oral antidiabetic drugs on nonalcoholic fatty liver disease. JAMA Internal Medicine,2024. https://doi.org/10.1001/jamainternmed.2023.8029

Powered by WPeMatico

Debunking the myth – Can individuals be marathon runners and still have diabetes? – Dr Ankit Manglunia

Maintaining HbA1c below 7% is crucial for individuals with diabetes. The HbA1c test assesses average blood sugar levels over months, offering a comprehensive view of diabetes control. This target signifies well-regulated blood sugar, reducing the risk of complications like heart disease and kidney issues. Regularly monitoring and achieving this goal contribute to effective diabetes management, promoting overall health and preventing potential long-term complications.

Contrary to the popular myth that being a marathon runner ensures immunity from diabetes, it’s essential to dispel this misconception. Diabetes is a complex condition influenced by various factors, including genetics and lifestyle. Marathon runners can indeed have diabetes, as it is not solely determined by physical fitness. Factors like genetic predisposition and overall health play significant roles. Regular health check-ups are crucial for all individuals, including marathon runners, to assess and manage diabetes risks, reinforcing the importance of a holistic approach to health beyond exercise.

In this video, Dr Ankit Manglunia, an Endocrinologist from Jaipur, Rajasthan, talks about the hbA1c test for diabetes and the importance of keeping the HbA1c levels below 7% while addressing the misconception that a marathon runner cannot have Diabetes.

Powered by WPeMatico

Intravenous ertapenem effective in hidradenitis suppurativa, concerns may arise due to antimicrobial resistance: JAMA

USA: A recent study published in JAMA Dermatology has shed light on the efficacy and durability of intravenous (IV) ertapenem therapy for recalcitrant hidradenitis suppurativa (HS)

The retrospective medical record review of 98 patients with HS revealed that IV ertapenem administration for an average of 13 weeks improved inflammatory and clinical markers and heightened patient satisfaction. However, the researchers suggest monitoring this approach to HS therapy for the emergence of antimicrobial resistance (AMR) due to the longer than standard treatment course.

“For patients with hidradenitis suppurativa who received IV ertapenem treatment over a mean of 13.1 weeks, there was a significant decrease in HS Physician Global Assessment score, C-reactive protein, a numerical rating scale for pain, interleukin-6, and leukocytes,” the researchers reported.

Hidradenitis suppurativa is a debilitating follicular skin disorder, in which bacterial colonization is typical. Advanced HS remains extremely challenging to treat. Oral antibiotic efficacy can be unreliable; however, selective intravenous antibiotics, such as ertapenem, may provide favourable clinical outcomes. Given this, Avigdor Nosrati, Division of Dermatology, Department of Medicine, Albert Einstein College of Medicine, New York, New York, and colleagues aimed to explore optimal course duration, efficacy, and patient satisfaction associated with IV ertapenem for HS.

For this purpose, the research team conducted a retrospective review of the medical records of 98 patients with HS between 2018 and 2022. Patient outcomes were measured and evaluated before and after treatment. Participants were followed up in a telephone survey assessing patient satisfaction and perspectives.

Patients were treated with 1 g of ertapenem, self-administered at home through a peripheral IV central catheter using an elastomeric pump for 12 to 16 weeks. Antiandrogens and immunomodulatory biologic therapies initiated before ertapenem were maintained throughout the treatment course. A total of 98 patients (mean age, 35.8 years; 62.2% female) with HS were treated with intravenous ertapenem.

The primary outcomes included a numerical rating scale for pain [an 11-point scale in which a score of 0 indicates no pain and a score of 10 indicates the worst possible pain]), markers of inflammation (such as leukocytes, C-reactive protein, erythrocyte sedimentation rate, and interleukin-6), and clinical severity (evaluated through the HS Physician Global Assessment score [a 6-point scale ranging from clear to very severe]. These outcomes were measured at baseline, the midcourse of IV ertapenem treatment, at the end of the course, and posttherapy. At these 4 points, bacterial abundance was also examined and patient satisfaction was assessed during follow-up.

The mean treatment duration spanned 13.1 weeks, with posttherapy follow-up occurring after 7.8 weeks.

The key findings of the study were as follows:

  • From baseline to posttherapy follow-up, significant reductions were found in the mean (SD) HS Physician Global Assessment scores (3.9 vs 2.7) and the numerical rating scale for pain (4.2 vs 1.8), C-reactive protein (5.4 vs 2.4 mg/dL), interleukin-6 (25.2 vs 13.7), and leukocytes (11.34 vs 10.0).
  • At follow-up, 78.0% of patients participated in the telephone survey, where 80.3% reported medium to high satisfaction; 90.8% would recommend ertapenem to other patients.

“The use of antibiotics continues to play a complementary role in the management of hidradenitis suppurativa as new immunomodulatory therapies are developed,” the researchers wrote.

“There is a need for larger, prospective, randomized clinical trials to further optimize ertapenem dosing and duration, to evaluate the coadministration of other therapies, and to develop strategies for maintaining therapeutic outcomes,” they concluded.

Reference:

Nosrati A, Ch’en PY, Torpey ME, et al. Efficacy and Durability of Intravenous Ertapenem Therapy for Recalcitrant Hidradenitis Suppurativa. JAMA Dermatol. Published online February 14, 2024. doi:10.1001/jamadermatol.2023.6201

Powered by WPeMatico

Cancer Care: GMC Jammu to soon get NGS testing facility

Jammu: The Government Medical College and Hospital (GMC), Jammu is going to be the first health institution in the Jammu region that will soon have an NGS (Next Generation Sequencing) testing facility for detecting and diagnosing early stage cancer.

The NGS facility is expected to start in the Jammu GMC by February, official sources said on Tuesday.

“The Jammu based Government Medical College and Hospital will have the NGS test facility by the end of February in the MicroBiology Department for early diagnosis of cancer-like symptoms,” sources said.

Also Read:GMC Jammu senior faculty members to supervise emergency services after working hours

The NGS is notably is a massively parallel sequencing technology that offers ultra-high throughput, scalability, and speed. The technology is used to determine the order of nucleotides in entire genomes or targeted regions of DNA or RNA.

Compared to traditional methods, NGS offers advantages in accuracy, sensitivity, and speed that have the potential to make a significant impact on the field of oncology.

Because NGS can assess multiple genes in a single assay, it eliminates the need to order multiple tests to identify the causative mutation.

Official sources said that detection of cancer in an advanced stage can help its prevention and treatment, adding that “in the first phase, 100 tests will be conducted in testing mode, and based upon the results, the facility will be a regular feature.”

They said that early detection can help the patient get timely treatment, and the start of the NGS test facility in Jammu will benefit the patients battling with the chronic disease.

A well-known oncologist and principal of Government Medical College and Hospital, Jammu, Dr (Prof) Ashutosh Sharma, told UNI, “We are on the job, and the NGS test facility is expected to begin in the hospital by the next two weeks.”

“Initially, it will start with breast cancer, and it will be the first of its kind facility in the GMC in the Jammu region,” said the Principal.

As per reports, over 55,000 cancer cases were detected in Jammu and Kashmir in the last five years.

According to the Health Ministry data, 12396 cancer cases were reported in the year 2019, 12726 in 2020, 13060 in 2021, and 13395 in 2022.

Mouth and lung cancer in men and cervical and breast cancer in women are responsible for 50 percent of deaths due to cancer in Jammu and Kashmir.

“More than 6,000 cancer cases have been registered at the State Cancer Institute Jammu in the last year,” official sources said.

Powered by WPeMatico

Tradipitant Shows Promise in Alleviating Nausea in Gastroparesis

Neurokinin receptor 1 (NK1R) antagonists have shown efficacy in reducing nausea and vomiting in various conditions, including chemotherapy-induced emesis. However, their effectiveness in gastroparesis remained uncertain. A recent study explored the safety and efficacy of tradipitant, a neurokinin receptor 1 (NK1R) antagonist, in patients with idiopathic and diabetic gastroparesis. Gastroparesis is a condition characterized by delayed gastric emptying, leading to symptoms such as nausea and vomiting. Tradipitant, known for its effectiveness in chemotherapy-induced emesis, was investigated for its potential in treating gastroparesis-related symptoms.

This study was published in the journal Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association by Jesse L Carlin and colleagues. This study aimed to evaluate the safety and efficacy of tradipitant in alleviating symptoms of nausea in patients with gastroparesis.

The study included 201 adults with gastroparesis who were randomly assigned to receive either oral tradipitant 85 mg or placebo twice daily for 12 weeks. Symptoms were assessed using daily symptom diaries, Gastroparesis Cardinal Symptom Index scores, and other patient-reported questionnaires. Blood levels were monitored for an exposure-response analysis. The primary outcome measure was the change from baseline to week 12 in average nausea severity, as measured by the daily symptom diary.

  • Primary Outcome: The intention-to-treat (ITT) population did not show a significant difference in nausea severity change between the tradipitant and placebo groups at week 12 (P = .741).

  • Exposure-Response Analysis: Post hoc analyses, considering factors such as drug exposure, rescue medications, and baseline severity inflation, revealed significant improvements in average nausea severity in subjects with high blood levels of tradipitant starting from weeks 2 through 4.

  • Sensitivity Analyses: When accounting for confounding factors, tradipitant treatment demonstrated strengthened effects, with statistically significant improvements in nausea observed at week 12.

While tradipitant did not achieve significance in the ITT population, the study’s exposure-response analysis indicated significant effects with adequate tradipitant exposure. Post hoc sensitivity analyses further supported the potential of tradipitant as a treatment for nausea in gastroparesis patients. These findings highlight the need for further research to explore tradipitant’s efficacy in managing gastroparesis symptoms.

Reference:

Carlin, J. L., Polymeropoulos, C., Camilleri, M., Lembo, A., Fisher, M., Kupersmith, C., Madonick, D., Moszczynski, P., Smieszek, S., Xiao, C., Birznieks, G., & Polymeropoulos, M. H. The efficacy of tradipitant in patients with diabetic and idiopathic gastroparesis in phase III randomized placebo-controlled clinical trial. Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association,2024. https://doi.org/10.1016/j.cgh.2024.01.005

Powered by WPeMatico

Walking, jogging, yoga, and strength training may ease depression: Study

Walking or jogging, yoga, and strength training seem to be the most effective exercises to ease depression, either alone or alongside established treatments such as psychotherapy and drugs, suggests an evidence review published by The BMJ today.

Even low intensity activities such as walking or yoga are beneficial, but the results suggest that the more vigorous the activity, the greater the benefits are likely to be.

The authors stress that confidence in many of the findings remains low and more high quality studies are needed, but they say these forms of exercise “could be considered alongside psychotherapy and drugs as core treatments for depression.”

The World Health Organization estimates that more than 300 million people worldwide have depression. Exercise is often recommended alongside psychotherapy and drugs, but treatment guidelines and previous evidence reviews disagree on how to prescribe exercise to best treat depression.

To address this uncertainty, researchers trawled databases looking for randomised trials that compared exercise as a treatment for depression with established treatments (eg, SSRI antidepressants, cognitive behavioural therapy), active controls (eg, usual care, placebo tablet), or untreated controls.

They found 218 relevant trials involving 14,170 participants with depression for analysis. Each trial was assessed for bias and the type, intensity and frequency of each exercise intervention was recorded.

Other potentially influential factors such as participants’ sex, age, baseline levels of depression, existing conditions, and differences between groups were also taken into account.

Compared with active controls, large reductions in depression were found for dance and moderate reductions for walking or jogging, yoga, strength training, mixed aerobic exercises and tai chi or qigong.

Moderate, clinically meaningful effects were also found when exercise was combined with SSRIs or aerobic exercise was combined with psychotherapy, suggesting that exercise could provide added benefit alongside these established treatments.

Although walking or jogging were effective for both men and women, strength training was more effective for women, and yoga or qigong was more effective for men. Yoga was also more effective among older adults, while strength training was more effective among younger people.

And while light physical activity such as walking and yoga still provided clinically meaningful effects, the benefits were greater for vigorous exercise such as running and interval training.

Exercise appeared equally effective for people with and without other health conditions and with different baseline levels of depression. Effects were also similar for individual and group exercise.

The authors acknowledge that the quality of evidence is low and very few trials monitored participants for one year or more. Many patients may also have physical, psychological, or social barriers to participation, they note.

Nevertheless, they suggest a combination of social interaction, mindfulness, and immersion in green spaces that may help explain the positive effects.

“Our findings support the inclusion of exercise as part of clinical practice guidelines for depression, particularly vigorous intensity exercise,” they say. “Health systems may want to provide these treatments as alternatives or adjuvants to other established interventions, while also attenuating risks to physical health associated with depression.”

“Primary care clinicians can now recommend exercise, psychotherapy, or antidepressants as standalone alternatives for adults with mild or moderate depression,” explains Juan Ángel Bellón at the University of Malaga in a linked editorial.

He points out that taking regular exercise can be challenging for people with depression and says studies using real world data are needed to evaluate physical activity programmes for people with depression.

He notes that the European Union has recently committed to promoting exercise across member states and urges health services and local and national administrations to “provide enough resources to make individualised and supervised exercise programmes accessible to the entire population.”

Reference:

https://www.bmj.com/content/384/bmj-2023-075847

Powered by WPeMatico

Lymphocytosis linked to higher prevalence of hypothyroidism in patients with obstructive sleep apnea

China: A recent study published in BMC Pulmonary Medicine has revealed an increase in the prevalence of hypothyroidism in patients with obstructive sleep apnea (OSA) with increases in the number of lymphocytes.

The findings suggest that lymphocyte count can be used as an independent predictor of hypothyroidism occurrence and has diagnostic value for OSA combined with hypothyroidism.

Obstructive sleep apnea is a common sleep-breathing disorder. Several studies have revealed a strong inherent relationship between OSA and hypothyroidism. Studies indicate that lymphocytes may be involved in hypothyroidism development in OSA patients. Jing Zhang from the Department of Respiratory and Critical Care Medicine in Tianjin Medical University General Hospital, Tianjin, China, and colleagues aimed to assess the association between lymphocytes and hypothyroidism in OSA patients.

The study included 920 patients with obstructive sleep apnea who underwent nocturnal sleep monitoring, routine blood tests, and thyroid function testing. In OSA patients, logistic regression analysis indicated independent predictors of hypothyroidism.

The cutoff level of lymphocyte count was determined using a receiver operating characteristic (ROC) analysis to predict the occurrence of hypothyroidism in patients with OSA.

The study led to the following findings:

· The study comprised 920 OSA patients (617 males and 303 women), 879 with normal thyroid function, and 41 with hypothyroidism, with a hypothyroidism incidence of 4.46%.

· In the entire OSA population and male OSA patients, the number of lymphocytes was significantly higher in the hypothyroid group than in the control group.

· Among the OSA population younger than 60 years old and patients with mild to moderate OSA, lymphocytes were considerably more in the hypothyroid group than in the euthyroid group.

· Lymphocyte count, sex, and Epworth Sleepiness Scale (ESS) were all independent predictors of hypothyroidism development in OSA patients.

· According to ROC curve analysis, the risk of hypothyroidism increases with increasing lymphocyte count in the total patient population, with an optimal diagnostic cutoff point of 2.5 (× 10*9/L).

Based on the findings, lymphocyte levels tend to be higher in OSA patients who also have hypothyroidism, and this association is particularly significant in the overall OSA population and male patients.

Furthermore, the researchers discovered that lymphocyte count independently predicts hypothyroidism development in patients with OSA, which has not been previously reported.

“A simple blood test for lymphocyte count in OSA patients could indicate the occurrence of hypothyroidism in OSA patients, proving crucial in clinical practice,” the researchers wrote.

Study limitations include a small sample size because of the exclusion of some patients with OSA, the lack of evaluation of continuous positive airway pressure or hormone supplementation on lymphocyte levels, and the lack of long-term follow-up.

Reference:

Fang, X., Wang, L., Xu, C. et al. The association of lymphocyte with hypothyroidism in obstructive sleep apnea. BMC Pulm Med 24, 60 (2024). https://doi.org/10.1186/s12890-024-02872-7

Powered by WPeMatico

Novel antibiotic Gepotidacin safe, tolerable and effective option against UTI: Lancet

In a recent study, a novel antibiotic, the Gepotidacin has demonstrated promising efficacy and safety in clinical trials against urinary tract infections (UTIs). Gepotidacin was developed as a first-in-class triazaacenaphthylene antibiotic and it works by inhibiting bacterial DNA replication through a unique mechanism of action. The findings were published in The Lancet Journal.

The two Phase 3 trials, EAGLE-2 and EAGLE-3 were conducted on adolescent and adult females with uncomplicated UTIs and compared the efficacy and safety of oral Gepotidacin with that of nitrofurantoin which is commonly prescribed antibiotic for UTIs.

The participants in the trials received either oral Gepotidacin or nitrofurantoin for five days and the results showed that Gepotidacin was non-inferior to nitrofurantoin in both studies. In EAGLE-3, the Gepotidacin expressed superiority over nitrofurantoin and highlighted its potential as a potential option for UTI treatment.

Gepotidacin demonstrated a well-balanced inhibition of two type II topoisomerase enzymes that makes it effective against a wide range of bacterias causing UTI, including the drug-resistant strains. Despite its efficacy, the safety profile of Gepotidacin remained favorable. The most common adverse event associated with Gepotidacin was diarrhea, that was observed in a small percentage of patients, while nausea was the predominant adverse event with nitrofurantoin. Also, all adverse events were mostly mild or moderate, with no life-threatening occurrences being reported.

These findings underscore the potential of Gepotidacin as an essential addition to the antibiotic arsenal against urinary tract infections. With its distinct mechanism of action and broad-spectrum activity against the common uropathogens, including drug-resistant variants, Gepotidacin positively addresses the growing challenge of antibiotic resistance and improving outcomes for patients suffering from UTIs. Further studies on Gepotidacin would offer strong hope in the ongoing treatment against urinary tract infections through new approaches for effective treatment and relief.

Source:

Wagenlehner, F., Perry, C.R., Hooton, T.M., Scangarella-Oman, N.E., Millns, H., Powell, M., Jarvis, E., Dennison, J., Sheets, A., Butler, D., Breton, J., & Janmohamed, S. (2024). Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials. The Lancet. https://doi.org/10.1016/S0140-6736(23)02196-7

Powered by WPeMatico

Perfusion Index not reliable predictor of cardiac arrest compared to End-Tidal Carbon Dioxide for Hemodynamic Monitoring

Globally, cardiac arrest is one of the major causes of mortality; nonetheless, hospital survival and release rates with favourable neurological outcomes are still quite low. 9.0% of out-of-hospital cardiac arrests (OHCAs) and 23.3% of in-hospital cardiac arrests (IHCAs) resulted in hospital discharges, according to the American Heart Association (AHA). Parameters like intraarterial pressure monitoring and end-tidal carbon dioxide (EtCO2) are utilised during cardiopulmonary resuscitation (CPR) to track the efficacy of the procedure and estimate the prognosis. Low EtCO2 levels are indicative of subpar CPR, however sharp rises might be a sign of the spontaneous circulation returning (ROSC).

In addition to hemodynamic monitoring in the form of pulse oximetry, additional monitoring methods used in medicine include photoplethysmography (PPG) and perfusion index (PI). PPG is rapid, affordable, objectively repeatable, and simple to test. There is, however, little data about PI’s usefulness in cardiac arrest patients. Recently published research assessed how well PI and EtCO2 predict ROSC in individuals who have had cardiac arrest.

From November 1, 2018, to April 30, 2019, the research was carried out in the emergency department of Hacettepe University Hospital utilising the advanced cardiac life support protocol (ACLS), in accordance with the guidelines provided by the American Heart Association and the International Liaison Committee on Resuscitation (ILCOR). Both resuscitations revolve on providing excellent CPR and defibrillation. Using the LIFEPAK® 15 monitor/defibrillator and the Masimo Signal Extraction Technology (SET®) Radical 7 pulse device, patients were grouped based on ROSC and monitored.

The purpose of this investigation was to evaluate how well the Perfusion Index (PI) predicted cardiac arrest patients’ restoration of spontaneous circulation (ROSC). The ability of end-tidal carbon dioxide (ETCO2) to predict ROSC in individuals undergoing cardiac arrest as well as the correlation between PI and EtCO2 levels were the secondary outcomes. A total of 162 instances of cardiac arrest were recorded; the patients’ mean age was 70.4 ± 13.4, and 65% of them were men. Of the patients, 29 (29%) obtained the ROSC.

To forecast the ROSC, the values of PI and EtCO2 were looked at. The PI values did not vary statistically across the groups. But beginning in the fifth minute, the ROSC (+) group’s EtCO2 readings were noticeably greater than those of the ROSC (-) group. After the 25th minute, the sample size significantly decreased, making comparison and further analysis impossible.

To investigate the relationship between the EtCO2 concentrations and PI, Spearman correlation analysis were carried out. Between the PI and ETCO2 at0,5,10,15, 20, and 25 minutes, there was no association. The research emphasises how crucial it is to comprehend how PI and EtCO2 readings relate to one another in order to anticipate the ROSC in individuals who have had cardiac arrest.

The usage of PI and EtCO2 in cardiac arrest patients was compared in the research since hemodynamic monitoring depends on these measures. The PI values of the groups with and without the ROSC did not significantly change, according to the data. Nevertheless, from the fifth minute on, the ROSC group’s EtCO2 readings continued to be considerably higher, indicating that EtCO2 could provide insights into the outcomes of cardiac resuscitation. This implies that monitoring hemodynamic parameters—particularly those related to the use of EtCO2—may be essential for assessing the efficacy of resuscitation and formulating focused treatment plans in the context of cardiac arrest care. The lack of a significant correlation between PI readings and the ROSC suggests that PI may not be a very reliable predictor of cardiac arrest. The single-center design, the inclusion of only intubated patients, and the exclusion of non-intubated patients are among the limitations of this research. Nonetheless, the study projects that as technology advances, EtCO2 will become more widely used. Appropriate techniques will be used to do more research on individuals who are not intubated.

Reference –

Dogan B, Kudu E, Danış F, et al. (December 20, 2023) Comparative Analysis of Perfusion Index and End-Tidal Carbon Dioxide in Cardiac Arrest Patients: Implications for Hemodynamic Monitoring and Resuscitation Outcomes. Cureus 15(12): e50818. doi:10.7759/cureus.50818

Powered by WPeMatico